{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:03:44Z","timestamp":1794243824479,"version":"4.9.0"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.critrevonc.2024.104444","type":"journal-article","created":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T16:01:59Z","timestamp":1720886519000},"page":"104444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Integrating nutrition, physical exercise, psychosocial support and antiemetic drugs into CINV management: The road to success"],"prefix":"10.1016","volume":"201","author":[{"given":"Lorenzo","family":"Belluomini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Avancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Sposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Pontolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Tregnago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Trestini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Insolda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Carbognin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Milella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Bria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2229-4874","authenticated-orcid":false,"given":"Sara","family":"Pilotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.critrevonc.2024.104444_bib1","article-title":"Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: a quantitative market research-based survey","volume":"1","author":"Aapro","year":"2018","journal-title":"Cancer Rep. (Hoboken)"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104444_bib2","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00520-015-2829-z","article-title":"Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial","volume":"24","author":"Abe","year":"2016","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104444_bib3","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.clnu.2017.06.017","article-title":"ESPEN expert group recommendations for action against cancer-related malnutrition","volume":"36","author":"Arends","year":"2017","journal-title":"Clin. Nutr."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104444_bib4","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1080\/17474086.2021.2007764","article-title":"Exercise and anemia in cancer patients: could it make the difference?","volume":"14","author":"Avancini","year":"2021","journal-title":"Expert Rev. Hematol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104444_bib5","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.ejso.2021.03.231","article-title":"Exercise prehabilitation in lung cancer: getting stronger to recover faster","volume":"47","author":"Avancini","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104444_bib6","doi-asserted-by":"crossref","DOI":"10.2144\/fsoa-2020-0165","article-title":"Multidisciplinary lifestyle intervention to manage pancreatic cancer-related cachexia: a case report","volume":"7","author":"Avancini","year":"2020","journal-title":"Future Sci. OA"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104444_bib7","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1080\/14737140.2021.1927720","article-title":"A multimodal approach to cancer-related cachexia: from theory to practice","volume":"21","author":"Avancini","year":"2021","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104444_bib8","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00520-006-0109-7","article-title":"The impact of chemotherapy-induced nausea and vomiting on health-related quality of life","volume":"15","author":"Ballatori","year":"2007","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.critrevonc.2024.104444_bib9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejphar.2013.09.075","article-title":"Neurochemical mechanisms and pharmacologic strategies in managing nausea and vomiting related to cyclic vomiting syndrome and other gastrointestinal disorders","volume":"722","author":"Bashashati","year":"2014","journal-title":"Eur. J. Pharm."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104444_bib10","doi-asserted-by":"crossref","first-page":"883","DOI":"10.6004\/jnccn.2017.0117","article-title":"NCCN guidelines insights: antiemesis, version 2.2017","volume":"15","author":"Berger","year":"2017","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104444_bib11","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3390\/cancers14041022","article-title":"Emetogenicity of antibody-drug conjugates (ADCs) in solid tumors with a focus on trastuzumab deruxtecan: insights from an italian expert panel","volume":"14","author":"Bianchini","year":"2022","journal-title":"Cancers"},{"issue":"14","key":"10.1016\/j.critrevonc.2024.104444_bib12","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1002\/cam4.2486","article-title":"Analysis of concordance with antiemetic guidelines in pediatric, adolescent, and young adult patients with cancer using a large-scale administrative database","volume":"8","author":"Bun","year":"2019","journal-title":"Cancer Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104444_bib13","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1249\/MSS.0000000000002116","article-title":"Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable","volume":"51","author":"Campbell","year":"2019","journal-title":"Med. Sci. Sports Exerc"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104444_bib14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1078155214524809","article-title":"Adherence to antiemetic guidelines and control of chemotherapy-induced nausea and vomiting (CINV) in a large hospital","volume":"21","author":"Caracuel","year":"2014","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.critrevonc.2024.104444_bib15","doi-asserted-by":"crossref","DOI":"10.2217\/fon-2022-0330","article-title":"Efficacy of the dexamethasone-sparing triplet regimen for preventing cisplatin-induced emesis: a combined analysis","author":"Celio","year":"2022","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104444_bib16","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1186\/s12885-019-6454-y","article-title":"Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence","volume":"19","author":"Celio","year":"2019","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104444_bib17","doi-asserted-by":"crossref","first-page":"e1854","DOI":"10.1002\/onco.13851","article-title":"Dexamethasone-sparing regimens with oral netupitant and palonosetron for the prevention of emesis caused by high-dose cisplatin: a randomized noninferiority study","volume":"26","author":"Celio","year":"2021","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104444_bib18","doi-asserted-by":"crossref","first-page":"E14","DOI":"10.1097\/NCC.0000000000000648","article-title":"Does the oral administration of ginger reduce chemotherapy-induced nausea and vomiting?: A meta-analysis of 10 randomized controlled trials","volume":"42","author":"Chang","year":"2019","journal-title":"Cancer Nurs."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104444_bib19","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/bjc.2014.612","article-title":"Randomised controlled trial on the effectiveness of home-based walking exercise on anxiety, depression and cancer-related symptoms in patients with lung cancer","volume":"112","author":"Chen","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104444_bib20","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1007\/s00520-020-05935-7","article-title":"Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature","volume":"29","author":"Chow","year":"2021","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104444_bib21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00520-017-3866-6","article-title":"Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses","volume":"26","author":"Clark-Snow","year":"2018","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104444_bib22","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00520-006-0173-z","article-title":"Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings","volume":"15","author":"Cohen","year":"2007","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104444_bib23","first-page":"76","article-title":"Acupuncture and acupressure for the management of chemotherapy-induced nausea and vomiting","volume":"16","author":"Collins","year":"2004","journal-title":"J. Am. Acad. Nurse Pr."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104444_bib24","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1055\/s-0041-1726136","article-title":"Chemotherapy-induced nausea and vomiting (CINV) with GI cancer chemotherapy: do we need CINV risk score over and above antiemetic guidelines in prescribing antiemetic regime?","volume":"9","author":"D'Souza","year":"2020","journal-title":"South Asian J. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104444_bib25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.critrevonc.2018.02.001","article-title":"Efficacy of neurokinin-1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis","volume":"124","author":"Di Maio","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104444_bib26","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1007\/s00520-019-04697-1","article-title":"Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): results of a European oncology nurse survey","volume":"27","author":"Dielenseger","year":"2019","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104444_bib27","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","article-title":"The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting","volume":"28","author":"Dranitsaris","year":"2017","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104444_bib28","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1365-2125.2010.03743.x","article-title":"Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting","volume":"70","author":"Duran","year":"2010","journal-title":"Br. J. Clin. Pharm."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104444_bib29","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s00520-002-0427-3","article-title":"Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study","volume":"11","author":"Fabi","year":"2003","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104444_bib30","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00520-012-1493-9","article-title":"The impact of chemotherapy-related nausea on patients' nutritional status, psychological distress and quality of life","volume":"21","author":"Farrell","year":"2013","journal-title":"Support Care Cancer"},{"issue":"2 Suppl 1","key":"10.1016\/j.critrevonc.2024.104444_bib31","first-page":"5","article-title":"Best practice management of CINV in oncology patients: I. Physiology and treatment of CINV. Multiple neurotransmitters and receptors and the need for combination therapeutic approaches","volume":"8","author":"Frame","year":"2010","journal-title":"J. Support Oncol."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2024.104444_bib32","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.12098","article-title":"Efficacy of olanzapine combined with the standard triplet antiemetic therapy for cisplatin-based chemotherapy: a sub-analysis of a randomized, double-blind, placebo-controlled trial (J-FORCE)","volume":"39","author":"Fujita","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104444_bib33","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1177\/1078155220938847","article-title":"Comparison of two different intravenous serotonin antagonists used for chemotherapy-induced nausea and vomiting prophylaxis in patients treated with moderately emetogenic risk regimens: A retrospective analysis from a large academic medical center","volume":"26","author":"Gamble","year":"2020","journal-title":"J Oncol Pharm Pract"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104444_bib34","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.1007\/s00520-022-07067-6","article-title":"Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study","volume":"30","author":"Gao","year":"2022","journal-title":"Support Care Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104444_bib35","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s00520-004-0662-x","article-title":"Chemotherapy-induced nausea and vomiting in routine practice: a European perspective","volume":"12","author":"Glaus","year":"2004","journal-title":"Support Care Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104444_bib36","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1093\/annonc\/mdu096","article-title":"A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy","volume":"25","author":"Gralla","year":"2014","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104444_bib37","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000431256","article-title":"Role of psychosocial variables on chemotherapy-induced nausea and vomiting and health-related quality of life among cancer patients: a European study","volume":"84","author":"Grassi","year":"2015","journal-title":"Psychother. Psychosom."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104444_bib38","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/cncr.20230","article-title":"Incidence of chemotherapy-induced nausea and emesis after modern antiemetics","volume":"100","author":"Grunberg","year":"2004","journal-title":"Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2024.104444_bib39","article-title":"Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art","volume":"19","author":"Grunberg","year":"2011","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104444_bib40","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00520-010-0915-9","article-title":"Impact on daily functioning and indirect\/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population","volume":"19","author":"Haiderali","year":"2011","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104444_bib41","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","article-title":"Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Hashimoto","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104444_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102195","article-title":"2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","author":"Herrstedt","year":"2024","journal-title":"ESMO Open"},{"issue":"23","key":"10.1016\/j.critrevonc.2024.104444_bib43","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra0706547","article-title":"Chemotherapy-induced nausea and vomiting","volume":"358","author":"Hesketh","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.critrevonc.2024.104444_bib44","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"28","key":"10.1016\/j.critrevonc.2024.104444_bib45","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","article-title":"Antiemetics: American society of clinical oncology clinical practice guideline update","volume":"35","author":"Hesketh","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104444_bib46","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00520-017-3936-9","article-title":"Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic","volume":"26","author":"Hesketh","year":"2018","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104444_bib47","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00520-010-1073-9","article-title":"Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study","volume":"20","author":"Hilarius","year":"2012","journal-title":"Support Care Cancer"},{"issue":"14","key":"10.1016\/j.critrevonc.2024.104444_bib48","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.7150\/jca.87169","article-title":"Doublet or triplet antiemetic prophylaxis for nausea and vomiting induced by trastuzumab deruxtecan: an open-label, randomized, and multicenter exploratory phase 2 study","volume":"14","author":"Iihara","year":"2023","journal-title":"J. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104444_bib49","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1200\/JCO.2017.74.4375","article-title":"Placebo-controlled, double-blinded phase iii study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3 with combined neurokinin-1 receptor antagonist and palonosetron in high-emetogenic chemotherapy","volume":"36","author":"Ito","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104444_bib50","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1186\/s12885-019-6310-0","article-title":"A single exercise session improves side-effects of chemotherapy in women with breast cancer: an observational study","volume":"19","author":"Johnsson","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104444_bib51","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00520-017-3857-7","article-title":"Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a systematic review and meta-analysis.","volume":"26","author":"Jordan","year":"2018","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104444_bib52","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00520-016-3332-x","article-title":"2016 Updated MASCC\/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents","volume":"25","author":"Jordan","year":"2017","journal-title":"Support Care Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104444_bib53","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00520-006-0186-7","article-title":"A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis","volume":"15","author":"Jordan","year":"2007","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.critrevonc.2024.104444_bib54","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejphar.2013.09.071","article-title":"Anticipatory nausea and vomiting due to chemotherapy","volume":"722","author":"Kamen","year":"2014","journal-title":"Eur. J. Pharm."},{"issue":"14","key":"10.1016\/j.critrevonc.2024.104444_bib55","doi-asserted-by":"crossref","first-page":"939","DOI":"10.2217\/fon-2020-0187","article-title":"Real-world evidence of NEPA, netupitant-palonosetron, in chemotherapy-induced nausea and vomiting prevention: effects on quality of life","volume":"16","author":"Karthaus","year":"2020","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104444_bib56","doi-asserted-by":"crossref","first-page":"469","DOI":"10.7314\/APJCP.2013.14.1.469","article-title":"Can granisetron injection used as primary prophylaxis improve the control of nausea and vomiting with low- emetogenic chemotherapy?","volume":"14","author":"Keat","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104444_bib57","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/NCC.0b013e3181f104bc","article-title":"Cochrane review summary for cancer nursing: acupuncture-point stimulation for chemotherapy-induced nausea or vomiting","volume":"33","author":"Konno","year":"2010","journal-title":"Cancer Nurs."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104444_bib58","doi-asserted-by":"crossref","first-page":"812","DOI":"10.2146\/ajhp160227","article-title":"New options and controversies in the management of chemotherapy-induced nausea and vomiting","volume":"74","author":"Koth","year":"2017","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104444_bib59","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1188\/08.ONF.830-835","article-title":"Nausea at the end of adjuvant cancer treatment in relation to exercise during treatment in patients with breast cancer","volume":"35","author":"Lee","year":"2008","journal-title":"Oncol. Nurs. Forum"},{"key":"10.1016\/j.critrevonc.2024.104444_bib60","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13020-020-00333-x","article-title":"Efficacy of acupuncture in the prevention and treatment of chemotherapy-induced nausea and vomiting in patients with advanced cancer: a multi-center, single-blind, randomized, sham-controlled clinical research","volume":"15","author":"Li","year":"2020","journal-title":"Chin. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104444_bib61","doi-asserted-by":"crossref","first-page":"13","DOI":"10.14218\/FIM.2022.00031","article-title":"Acupuncture in the prevention of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized controlled studies","volume":"1","author":"Liu","year":"2022","journal-title":"Future Integr. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104444_bib62","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/10408398.2013.865590","article-title":"Ginger-Mechanism of action in chemotherapy-induced nausea and vomiting: a review","volume":"57","author":"Marx","year":"2017","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"10.1016\/j.critrevonc.2024.104444_bib63","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijnurstu.2017.02.014","article-title":"Effects of acupressure on chemotherapy-induced nausea and vomiting-a systematic review with meta-analyses and trial sequential analysis of randomized controlled trials","volume":"70","author":"Miao","year":"2017","journal-title":"Int. J. Nurs. Stud."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104444_bib64","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1248\/bpb.b21-00198","article-title":"Palonosetron versus Granisetron in Combination with Aprepitant and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting after Moderately Emetogenic Chemotherapy: A Single-Institutional Retrospective Cohort Study","volume":"44","author":"Miyoshi","year":"2021","journal-title":"Biol Pharm Bull"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104444_bib65","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jpainsymman.2013.06.012","article-title":"Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study","volume":"47","author":"Molassiotis","year":"2014","journal-title":"J. Pain. Symptom Manag."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104444_bib66","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s00520-023-08225-0","article-title":"2023 MASCC\/ESMO consensus antiemetic guidelines related to integrative and non-pharmacological therapies","volume":"32","author":"Molassiotis","year":"2023","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104444_bib67","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.jpainsymman.2015.12.317","article-title":"Anticipatory nausea, risk factors, and its impact on chemotherapy-induced nausea and vomiting: results from the pan European emesis registry study","volume":"51","author":"Molassiotis","year":"2016","journal-title":"J. Pain. Symptom Manag."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104444_bib68","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00520-007-0343-7","article-title":"A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre","volume":"16","author":"Molassiotis","year":"2008","journal-title":"Support Care Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104444_bib69","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1007\/s00520-013-1843-2","article-title":"Development and preliminary validation of a risk prediction model for chemotherapy-related nausea and vomiting","volume":"21","author":"Molassiotis","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.critrevonc.2024.104444_bib70","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fphar.2020.00329","article-title":"Patient-related risk factors for chemotherapy-induced nausea and vomiting: a systematic review","volume":"11","author":"Mosa","year":"2020","journal-title":"Front Pharm."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104444_bib71","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.clnu.2021.02.005","article-title":"ESPEN practical guideline: clinical nutrition in cancer","volume":"40","author":"Muscaritoli","year":"2021","journal-title":"Clin. Nutr."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104444_bib72","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/01635581.2018.1527375","article-title":"Randomized study of the effect of dietary counseling during adjuvant chemotherapy on chemotherapy induced nausea and vomiting, and quality of life in patients with breast cancer","volume":"71","author":"Najafi","year":"2019","journal-title":"Nutr. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104444_bib73","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/jjco\/hyx084","article-title":"A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy","volume":"47","author":"Nakashima","year":"2017","journal-title":"Jpn J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104444_bib74","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejphar.2013.08.048","article-title":"Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting","volume":"722","author":"Navari","year":"2014","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.critrevonc.2024.104444_bib75","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/595894","article-title":"Treatment of breakthrough and refractory chemotherapy-induced nausea and vomiting","volume":"2015","author":"Navari","year":"2015","journal-title":"Biomed. Res. Int."},{"issue":"23","key":"10.1016\/j.critrevonc.2024.104444_bib76","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.2217\/fon-2021-0023","article-title":"Single-dose netupitant\/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis","volume":"17","author":"Navari","year":"2021","journal-title":"Future Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104444_bib77","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s00520-012-1710-6","article-title":"The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy","volume":"21","author":"Navari","year":"2013","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104444_bib78","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2024.104444_bib79","unstructured":"NCCNClinical Practice Guidelines in Oncology (NCCN Guidelines \u00ae)."},{"key":"10.1016\/j.critrevonc.2024.104444_bib80","unstructured":"Antiemesis. Version 1.2024 2023. (2023)."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104444_bib81","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1007\/s13187-020-01689-2","article-title":"Evaluation of adherence to antiemetic treatment guidelines in patients with chemotherapy-induced nausea and vomiting in teaching hospitals in Tehran","volume":"36","author":"Nikbakht","year":"2021","journal-title":"J. Cancer Educ."},{"issue":"1-2","key":"10.1016\/j.critrevonc.2024.104444_bib82","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.autneu.2010.05.001","article-title":"Acupuncture and cancer","volume":"157","author":"O'Regan","year":"2010","journal-title":"Auton. Neurosci."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104444_bib83","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1634\/theoncologist.2019-0133","article-title":"One-day versus three-day dexamethasone in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a systematic review and individual patient data-based meta-analysis","volume":"24","author":"Okada","year":"2019","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104444_bib84","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/jamaoncol.2016.4096","article-title":"Prescription of prophylactic antiemetic drugs for patients receiving chemotherapy with minimal and low emetic risk","volume":"3","author":"Okuyama","year":"2017","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104444_bib85","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/cam4.3693","article-title":"Elevated serum substance P level as a predictive marker for moderately emetogenic chemotherapy-induced nausea and vomiting: a prospective cohort study","volume":"10","author":"Park","year":"2021","journal-title":"Cancer Med"},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104444_bib86","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1249\/MSS.0000000000002117","article-title":"American college of sports medicine roundtable report on physical activity, sedentary behavior, and cancer prevention and control","volume":"51","author":"Patel","year":"2019","journal-title":"Med. Sci. Sports Exerc"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104444_bib87","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26542","article-title":"Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: a focused update","volume":"64","author":"Patel","year":"2017","journal-title":"Pedia Blood Cancer"},{"key":"10.1016\/j.critrevonc.2024.104444_bib88","doi-asserted-by":"crossref","DOI":"10.1007\/s00520-022-07287-w","article-title":"Interventions for the prevention of acute phase chemotherapy-induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis","author":"Patel","year":"2022","journal-title":"Support Care Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104444_bib89","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1007\/s00520-018-4120-6","article-title":"Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors","volume":"26","author":"Puri","year":"2018","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104444_bib90","first-page":"232","article-title":"Chemotherapy-induced nausea and vomiting: optimizing prevention and management","volume":"5","author":"Rao","year":"2012","journal-title":"Am. Health Drug Benefits"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104444_bib91","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s00520-010-0980-0","article-title":"Anticipatory nausea and vomiting","volume":"19","author":"Roscoe","year":"2011","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104444_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100553","article-title":"Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer","volume":"7","author":"Rugo","year":"2022","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104444_bib93","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(08)70313-9","article-title":"Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial","volume":"10","author":"Saito","year":"2009","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104444_bib94","first-page":"95","article-title":"Psychological interventions in chemotherapy-induced nausea and vomiting in women with breast cancer: a systematic review","volume":"47","author":"Samami","year":"2022","journal-title":"Iran. J. Med. Sci."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104444_bib95","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/ptr.6377","article-title":"The effect of ginger (Zingiber officinale) on chemotherapy-induced nausea and vomiting in breast cancer patients: a systematic literature review of randomized controlled trials","volume":"33","author":"Saneei Totmaj","year":"2019","journal-title":"Phytother. Res"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104444_bib96","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1002\/pon.4794","article-title":"Are psychological interventions effective on anxiety in cancer patients? A systematic review and meta-analyses","volume":"27","author":"Sanjida","year":"2018","journal-title":"Psychooncology"},{"key":"10.1016\/j.critrevonc.2024.104444_bib97","article-title":"Systematic review of yoga for symptom management during conventional treatment of breast cancer patients","volume":"48","author":"Selvan","year":"2022","journal-title":"Complement Ther. Clin. Pr."},{"key":"10.1016\/j.critrevonc.2024.104444_bib98","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.critrevonc.2015.12.001","article-title":"Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review","volume":"99","author":"Sommariva","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104444_bib99","doi-asserted-by":"crossref","DOI":"10.3390\/nu13020589","article-title":"Nutritional intervention contributes to the improvement of symptoms related to quality of life in breast cancer patients undergoing neoadjuvant chemotherapy: a randomized clinical trial","volume":"13","author":"Souza","year":"2021","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104444_bib100","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1159\/000511049","article-title":"Management of chemotherapy-induced nausea and vomiting with trastuzumab deruxtecan: a case series","volume":"16","author":"Stankowicz","year":"2021","journal-title":"Breast Care (Basel)"},{"key":"10.1016\/j.critrevonc.2024.104444_bib101","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.2147\/IJWH.S401938","article-title":"Oral tetrahydrocannabinol (THC): cannabinoid (CBD) cannabis extract adjuvant for reducing chemotherapy-induced nausea and vomiting (CINV): a randomized, double-blinded, placebo-controlled, crossover trial","volume":"15","author":"Sukpiriyagul","year":"2023","journal-title":"Int J. Women\u2019s. Health"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104444_bib102","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1634\/theoncologist.2020-0305","article-title":"Metoclopramide, dexamethasone, or palonosetron for prevention of delayed chemotherapy-induced nausea and vomiting after moderately emetogenic chemotherapy (MEDEA): a randomized, phase iii, noninferiority trial","volume":"26","author":"van der Vorst","year":"2021","journal-title":"Oncologist"},{"issue":"17","key":"10.1016\/j.critrevonc.2024.104444_bib103","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1200\/JCO.2014.59.1081","article-title":"Effect of low-intensity physical activity and moderate- to high-intensity physical exercise during adjuvant chemotherapy on physical fitness, fatigue, and chemotherapy completion rates: results of the PACES randomized clinical trial","volume":"33","author":"van Waart","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104444_bib104","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00432-013-1540-z","article-title":"Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity","volume":"140","author":"Vig","year":"2014","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104444_bib105","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph19073800","article-title":"Respiratory physiotherapy intervention strategies in the sequelae of breast cancer treatment: a systematic review","volume":"19","author":"Vinolo-Gil","year":"2022","journal-title":"Int J. Environ. Res Public Health"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104444_bib106","article-title":"I think I'm gonna hurl': a narrative review of the causes of nausea and vomiting in sport","volume":"7","author":"Wilson","year":"2019","journal-title":"Sports (Basel)"},{"key":"10.1016\/j.critrevonc.2024.104444_bib107","doi-asserted-by":"crossref","first-page":"6575","DOI":"10.2147\/CMAR.S254398","article-title":"Efficacy of olanzapine-triple antiemetic regimen in patients with gastrointestinal tumor and high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: a retrospective study","volume":"12","author":"Wu","year":"2020","journal-title":"Cancer Manag. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104444_bib108","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-021-08572-3","article-title":"Efficacy and safety of 5\u2009mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials","volume":"21","author":"Yamamoto","year":"2021","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104444_bib109","doi-asserted-by":"crossref","first-page":"12504","DOI":"10.1002\/cam4.5962","article-title":"Acupuncture for the prevention of chemotherapy-induced nausea and vomiting in cancer patients: a systematic review and meta-analysis","volume":"12","author":"Yan","year":"2023","journal-title":"Cancer Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104444_bib110","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10147-017-1200-4","article-title":"A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy","volume":"23","author":"Yanai","year":"2018","journal-title":"Int. J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104444_bib111","doi-asserted-by":"crossref","first-page":"e1870","DOI":"10.1002\/onco.13888","article-title":"A pragmatic study evaluating NEPA versus aprepitant for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy","volume":"26","author":"Zelek","year":"2021","journal-title":"Oncologist"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824001872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824001872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T11:25:19Z","timestamp":1723634719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824001872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":111,"alternative-id":["S1040842824001872"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104444","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrating nutrition, physical exercise, psychosocial support and antiemetic drugs into CINV management: The road to success","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104444","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104444"}}